Patents by Inventor Françoise LUCIANI

Françoise LUCIANI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10408841
    Abstract: Polypeptides of the p-ORF2 protein of the hepatitis E virus, including at least the amino acid sequence 394-660, numbered in relation to a p-ORF2 protein of 660 amino acids, in which the three cysteines at positions 627, 630 and 638 have been mutated or, for a p-ORF2 protein of different length, at least the amino acid sequence corresponding to amino acids 394-660 of the p-ORF2 protein of 660 amino acids, in which the three cysteines located at the three positions corresponding to positions 627, 630 and 638 of the p-ORF2 protein of 660 amino acids have been mutated. Also, methods for determining the presence of the humoral response or the titer of antibodies directed against the p-ORF2 protein using these polypeptides, and also the use thereof in the context of infection with the hepatitis E virus.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: September 10, 2019
    Assignee: BIOMERIEUX SA
    Inventors: Yasemin Ataman-Onal, Soizic Daniel, Nadège Goutagny, Françoise Luciani
  • Publication number: 20180328929
    Abstract: Polypeptides of the p-ORF2 protein of the hepatitis E virus, including at least the amino acid sequence 394-660, numbered in relation to a p-ORF2 protein of 660 amino acids, in which the three cysteines at positions 627, 630 and 638 have been mutated or, for a p-ORF2 protein of different length, at least the amino acid sequence corresponding to amino acids 394-660 of the p-ORF2 protein of 660 amino acids, in which the three cysteines located at the three positions corresponding to positions 627, 630 and 638 of the p-ORF2 protein of 660 amino acids have been mutated. Also, methods for determining the presence of the humoral response or the titer of antibodies directed against the p-ORF2 protein using these polypeptides, and also the use thereof in the context of infection with the hepatitis E virus.
    Type: Application
    Filed: November 29, 2016
    Publication date: November 15, 2018
    Applicants: BIOMERIEUX, BIOMERIEUX
    Inventors: Yasemin ATAMAN-ONAL, Soizic DANIEL, Nadège GOUTAGNY, Françoise LUCIANI